Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils

doi:10.1016/0304-3940(96)12340-5

Neuroscience Letters

Volume 204, Issues 1–2, 2 February 1996, Pages 109-112

https://doi.org/10.1016/0304-3940(96)12340-5 Get rights and content

Abstract

Interleukin-6 (IL-6) has been shown to have potent neurotrophic activity on peripheral and central neurons in vitro. However, it remains to be determined whether or not IL-6 rescues hippocampal CA1 neurons from lethal ischemia and prevents ischemia-induced learning disability. In the present in vivo study, we infused IL-6 continuously for 7 days into the lateral ventricle of gerbil starting 2 h before 3-min forebrain ischemia. IL-6 infusion prevented the occurrence of ischemia-induced learning disability in a dose-dependent manner as revealed by a step-down passive avoidance task. Subsequent light and electron microscopic examinations showed that pyramidal neurons in the CA1 region of the hippocampus as well as synapses within the strata moleculare, radiatum and oriens of the region were significantly more numerous in gerbils infused with IL-6 than in those receiving vehicle infusion. These findings suggest that IL-6 has a trophic effect on ischemic hippocampal neurons.

References (19)

H. Araki et al.
Behavioral, electroencephalographic and histopathological studies on Mongolian gerbils with occluded common carotid arteries
Physiol. Behav.
(1986)
T. Hama et al.
Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats
Neurosci. Lett.
(1989)
T. Kirino
Delayed neuronal death in the gerbil hippocampus following ischemia
Brain Res.
(1982)
T. Kishimoto
The biology of interleukin-6
Blood
(1989)
Y. Kushima et al.
Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium
Neurosci. Res.
(1992)
A. Mitani et al.
Transient forebrain ischemia of three-minute duration consistently induces severe neuronal damage in field CA1 of the hippocampus in the normothermic gerbil
Neurosci. Lett.
(1991)
N. Nakata et al.
Protective effects of basic fibroblast growth factor against hippocampal neuronal damage following cerebral ischemia in the gerbil
Brain Res.
(1993)
A. Sano et al.
Protection by prosaposin against ischemia-induced learning disability and neuronal loss
Biochem. Biophys. Res. Commun.
(1994)
B. Schöbitz et al.
Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain
Neurosci. Lett.
(1992)

There are more references available in the full text version of this article.

Cited by (109)

Plasmatic profiles of cytokines/chemokines, glial fibrillary acidic protein (GFAP) and MRI brain damage in neonates with hypoxic ischemic encephalopathy (HIE)
2024, Cytokine
Perinatal hypoxia triggers the release of cytokines and chemokines by neurons, astrocytes and microglia. In response to hypoxia–ischemia resting/ramified microglia proliferate and undergo activation, producing proinflammatory molecules. The brain damage extension seems to be related to both the severity of hypoxia and the balance between pro and anti-inflammatory response and can be explored with neuroimaging.
The aim of this preliminary study was to explore possible relationships between plasma levels of inflammatory cytokines/chemokines and the severe brain damage detectable by Magnetic Resonance Imaging (MRI), performed during the hospitalization.
In 10 full terms neonates with hypoxic ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH), divided into cases and controls, according to MRI results, we measured and compared the plasma levels of CCL2/MCP-1, CXCL8, GFAP, IFN y, IL-10, IL-18, IL-6, CCL3, ENOLASE2, GM-CSF, IL-1b, IL-12p70, IL-33, TNFα, collected at four different time points during TH (24, 25–48, 49–72 h of life, and 7–10 days from birth). Five of enrolled babies had pathological brain MRI (cases) and 5 had a normal MRI examination (controls). Cytokines were measured by Magnetic Luminex Assay. MRI images were classified according to Barkovich’s score.
Mean levels of all cytokines and molecules at time T1 were not significantly different in the two groups. Comparing samples paired by day of collection, the greatest differences between cases and controls were found at times T2 and T3, during TH. At T4, levels tended to get closer again (except for IL-6, IL10 and IL18). Infants with worse MRI showed higher plasmatic GFAP levels than those with normal MRI, while their IL-18 was lower. The mean levels of CCL3MIP1alpha, GMCSF, IL1BETA overlapped throughout the observation period in both groups.
In a small number of infants with worse brain MRI, we found higher levels of GFAP and of IL-10 at T4 and a trend toward low IL-18 levels than in infants with normal MRI, considered early biomarker of brain damage and a predictor of adverse outcome, respectively. The greatest, although not significant, difference between the levels of molecules was found in cases and controls at time points T2 and T3, during TH.
Inflammation, brain structure and cognition interrelations among individuals with differential risks for bipolar disorder
2020, Brain, Behavior, and Immunity
Citation Excerpt :
In some conditions IL-6 may play a protective role. Administration of IL-6 could partly protect memory deterioration caused by the amnesic drug scopolamine (Bianchi et al., 1997) as well as in animal model of ischemia (Matsuda et al., 1996). In humans, chronic fatigue syndrome (CFS) patients and healthy controls were administered exogenous IL-6 to temporarily activate the acute inflammatory response, and their neurocognitive performance was unexpectedly improved (Arnold et al., 2002).
Neuro-inflammation might impact on clinical manifestations and cognition function via changing the volumes of key brain structures such as the anterior cingulate cortex (ACC) in bipolar disorder (BD). In this study, we investigated the interrelations among interleukin (IL)-6 cytokine level, grey matter (GM) volume of the anterior cingulated cortex (ACC), and attention function among offspring of parents diagnosed with BD. The offspring were categorized as being either asymptomatic or symptomatic based on whether they manifested pre-defined sub-threshold mood symptoms. We found that the symptomatic offspring showed significantly higher serum levels of IL-6 than the asymptomatic offspring (F_{(1, 59)} = 67.65, p < 0.001). On the brain level, we obtained significant interactive effect of group and IL6 level on the ACC GM (P_FWE = 0.017). Specifically, the GM volume of the rostral ACC was negatively associated with the levels of IL-6 in the asymptomatic offspring (P_FWE = 0.021), but not the symptomatic offspring (P_FWE > 0.05). Mediation analyses revealed that the GM volume of the rostral ACC significantly mediated the negative association between the IL-6 levels and attention performance in the asymptomatic offspring (bootstrapping Confidence Interval (CI) = −6.0432 to −0.0731) but not the symptomatic offspring (bootstrapping CI = −0.3197 to 1.3423). Our data suggest that the asymptomatic and symptomatic bipolar offspring may exhibit different neurocognitive-inflammatory profiles, which could be further validated as viable biosignatures for BD risk and resilience.
Limitation by Rho-kinase and Rac of transforming growth factor-β-induced interleukin-6 release from astrocytes
2019, Neuroscience Letters
Transforming growth factor (TGF)-β stimulates release of interleukin (IL)-6, which is recognized to function as both a pro- and anti- inflammatory cytokine in the central nervous system, from astrocytes. It is generally recognized that effects of TGF-β are mediated through Smad-independent as well as Smad-dependent pathways. Small GTPases regulate a variety of cell functions. In the present study, we investigated whether or not Rho-kinase, a downstream effector of Rho, and Rac are implicated in TGF-β-stimulated IL-6 release from astrocytes (C8D1A cells). Y-27632 or fasudil (Rho-kinase inhibitors) or NSC23766 (an inhibitor of Rac-guanine nucleotide exchange factor interaction) significantly enhanced TGF-β-stimulated IL-6 release from these cells. TGF-β-stimulated IL-6 release was markedly upregulated in RhoA- or Rac-knockdown C8D1A cells. We found that SIS3 (a specific inhibitor of TGF-β-dependent Smad3 phosphorylation) or LY364947 (a TGF-β type I receptor kinase inhibitor) significantly reduced the IL-6 release. However, TGF-β-induced-Smad2 and Smad3 phosphorylation was not affected by Y-27632, fasudil or NSC23766. In conclusion, our results strongly suggest that Rho-kinase and Rac limit TGF-β-induced IL-6 release from astrocytes, and the suppressive effects are exerted independently of the Smad pathway or at a point downstream of Smad2/3 complex.
Beneficial potential of intravenously administered IL-6 in improving outcome after murine experimental stroke
2017, Brain, Behavior, and Immunity
Citation Excerpt :
Interleukin-6 (IL-6) is a pleiotropic cytokine, which has been extensively investigated in a variety of diseases (Kishimoto, 1989; Wolf et al., 2014), including ischemic stroke where its role is still disputed (Jung et al., 2011; Loddick et al., 1998; Matsuda et al., 1996; Suzuki et al., 2009).
Interleukin-6 (IL-6) is a pleiotropic cytokine with neuroprotective properties. Still, the therapeutic potential of IL-6 after experimental stroke has not yet been investigated in a clinically relevant way. Here, we investigated the therapeutic use of intravenously administered IL-6 and the soluble IL-6 receptor (sIL-6R) alone or in combination, early after permanent middle cerebral artery occlusion (pMCAo) in mice. IL-6 did not affect the infarct volume in C57BL/6 mice, at neither 24 nor 72 h after pMCAo but reduced the infarct volume in IL-6 knockout mice at 24 h after pMCAo. Assessment of post-stroke behavior showed an improved grip strength after a single IL-6 injection and also improved rotarod endurance after two injections, in C57BL/6 mice at 24 h. An improved grip strength and a better preservation of sensory functions was also observed in IL-6 treated IL-6 knockout mice 24 h after pMCAo. Co-administration of IL-6 and sIL-6R increased the infarct volume, the number of infiltrating polymorphonuclear leukocytes and impaired the rotarod endurance of C57BL/6 mice 24 h after pMCAo. IL-6 administration to naïve C57BL/6 mice lead after 45 min to increased plasma-levels of CXCL1 and IL-10, whereas IL-6 administration to C57BL/6 mice lead to a reduction in the ischemia-induced increase in IL-6 and CXCL1 at both mRNA and protein level in brain, and of IL-6 and CXCL1 in serum. We also investigated the expression of IL-6 and IL-6R after pMCAo and found that cortical neurons upregulated IL-6 mRNA and protein, and upregulated IL-6R after pMCAo. In conclusion, the results show a complex but potentially beneficial effect of intravenously administered IL-6 in experimental stroke.
Neuroprotective effect of mesenchymal stem cell through complement component 3 downregulation after transient focal cerebral ischemia in mice
2016, Neuroscience Letters
Citation Excerpt :
MSC treatment is likely increased IL-6 expression in injured brains, which would present itself as a neuroprotective effect on cerebral ischemia. Our observation is consistent with other reports that the injection of IL-6 showed the neuroprotective effects while the blockade of IL-6 signaling aggravated neuronal damage [23–26]. The chemokines, CCL-2 and CXCL-2, were increased in the brain during the acute phase of the MSCs-treated group after tFCI.
Bone marrow-derived mesenchymal stem cells (MSCs) are used in stroke treatment despite the poor understanding of its mode of action. The immune suppressive and anti-inflammatory properties of MSCs possibly play important roles in regulating neuroinflammation after stroke. We investigated whether MSCs reduce the inflammatory complement component 3 (C3) levels, thus, providing neuroprotection during stroke. Mice were subjected to transient focal cerebral ischemia (tFCI), after which MSCs were intravenously injected. The infarct volume of the brain was reduced in MSC-injected tFCI mice, and C3 expression was significantly reduced in both the brain and the blood. Additionally, the profiles of other inflammatory mediators demonstrated neuroprotective changes in the MSCs-treated group. In order to analyze the effect of MSCs on neurons during cerebral ischemia, primary cortical neurons were co-cultured with MSCs under oxygen-glucose deprivation (OGD). Primary neurons co-cultured with MSCs exhibited reduced levels of C3 expression and increased protection against OGD, indicating that treatment with MSCs reduces excessive C3 expression and rescues ischemia-induced neuronal damage. Our finding suggests that reduction of C3 expression by MSCs can help to ameliorate ischemic brain damage, offering a new neuroprotective strategy in stroke therapy.
Evidence that meningeal mast cells can worsen stroke pathology in mice
2014, American Journal of Pathology
Stroke is the leading cause of adult disability and the fourth most common cause of death in the United States. Inflammation is thought to play an important role in stroke pathology, but the factors that promote inflammation in this setting remain to be fully defined. An understudied but important factor is the role of meningeal-located immune cells in modulating brain pathology. Although different immune cells traffic through meningeal vessels en route to the brain, mature mast cells do not circulate but are resident in the meninges. With the use of genetic and cell transfer approaches in mice, we identified evidence that meningeal mast cells can importantly contribute to the key features of stroke pathology, including infiltration of granulocytes and activated macrophages, brain swelling, and infarct size. We also obtained evidence that two mast cell-derived products, interleukin-6 and, to a lesser extent, chemokine (C-C motif) ligand 7, can contribute to stroke pathology. These findings indicate a novel role for mast cells in the meninges, the membranes that envelop the brain, as potential gatekeepers for modulating brain inflammation and pathology after stroke.

View all citing articles on Scopus

View full text

Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils

Abstract

Physiol. Behav.

Neurosci. Lett.

Brain Res.

Blood

Neurosci. Res.

Neurosci. Lett.

Brain Res.

Biochem. Biophys. Res. Commun.

Neurosci. Lett.